Orelabrutinib Not Yet Recruiting Phase 2 Trials for B-Cell Lymphoma Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05014100Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma